Market Opportunity Bio-Me offers microbiome analysis services with PMP™ technology, targeting healthcare institutions, pharmaceutical companies, and consumer care brands globally. Sales potential exists in pharma companion diagnostics, microbiome-guided therapies, and consumer wellness product development.

Low Revenue Flag Current revenue is under $1M, indicating a growth stage with room for upsell, service expansion, and higher-margin custom assay development collaborations with strategic partners.

SME & Startup Fit Small to mid-sized biotech and diagnostics players, including potential genomics startups and CROs, are likely to seek PMP™ based profiling and assay design capabilities to accelerate R&D and clinical validation.

Global Collaboration Oslo-based Bio-Me’s international partnerships suggest opportunities to pursue regional pharma clients, contract research, and academic collaborations in Europe, North America, and Asia through co-development and hosted service models.

Data & IP Leverage Proprietary assay database and PMP™ platform can be monetized via licensing, custom assay development, and milestone-based collaborations, especially with partners requiring standardized, validated microbiome tests across gut, skin, and vaginal niches.